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Background: Gliomas are the most common human brain tumors. Glioblastoma, also known as glioblastoma
multiform (GBM), is the most aggressive, malignant, and lethal glioma. The investigation of prognostic and diagnostic
molecular biomarkers in glioma patients to provide direction on clinical practice is urgent. Recent studies demonstrated
that abnormal DNA methylation states play a key role in the pathogenesis of this kind of tumor. In this study, we want
to identify a novel biomarker related to glioma initiation and find the role of the glioma-related gene.
Methods: We performed a methylation-specific microarray on the promoter region to identify methylation gene(s) that
may affect outcome of GBM patients. Normal and GBM tissues were collected from Tiantan Hospital. Genomic DNA was
extracted from these tissues and analyzed with a DNA promoter methylation microarray. Testis derived transcript (TES)
protein expression was analyzed by immunohistochemistry in paraffin-embedded patient tissues. Western blotting was
used to detect TES protein expression in the GBM cell line U251 with or without 5-aza-dC treatment. Cell apoptosis was
evaluated by flow cytometry analysis using Annexin V/PI staining.
Results: We found that the TES promoter was hypermethylated in GBM compared to normal brain tissues under DNA
promoter methylation microarray analysis. The GBM patients with TES hypermethylation had a short overall survival
(P <0.05, log-rank test). Among GBM samples, reduced TES protein level was detected in 33 (89.2%) of 37
tumor tissues by immunohistochemical staining. Down regulation of TES was also correlated with worse patient
outcome (P <0.05, log-rank test). Treatment on the GBM cell line U251 with 5-aza-dC can greatly increase TES
expression, confirming the hypermethylation of TES promoter in GBM. Up-regulation of TES prompts U251
apoptosis significantly. This study demonstrated that both TES promoter hypermethylation and down-regulated
protein expression significantly correlated with worse patient outcome. Treatment on the GBM cell line (U251) with
5-aza-dC can highly release TES expression resulting in significant apoptosis in these cells.
Conclusions: Our findings suggest that the TES gene is a novel tumor suppressor gene and might represent a valuable
prognostic marker for glioblastoma, indicating a potential target for future GBM therapy.
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Gliomas are the most common central nervous system
tumor in adults. Glioblastoma, also known as glioblast-
oma multiform (GBM), is the most aggressive, malignant,
and lethal glioma. Despite radiation and temozolomide
therapy, the prognosis of patients with GBM remains
extremely poor, with a median survival time of only
14.5 months from diagnosis to death [1-3]. Recently,
DNA methylation alterations have been widely reported
in human gliomas, including global hypomethylation
and promoter-associated CpG island hypermethylation
[4]. To better understand the molecular mechanisms
and pathological effects of genomic methylation abnor-
mality on GBM, we performed genome-wide DNA methy-
lation analysis on GBM (n = 42) and normal brain tissues
(n = 8). We found that the testis derived transcript (TES)
gene promoter was broadly hypermethylated in GBM
patients.
The TES gene encodes a protein (Tes) of 421 amino
acids which plays a role in protein ? protein interactions
[5,6]. TES has an important role in cell adhesions and
largely affects cell motility in a vast number of cancers
[7]. According to recent studies, TES is widely consid-
ered as a putative tumor suppressor gene in malignances
such as head and neck squamous cell carcinomas [8],
ovarian cancer [9], primary gastric cancer [10], and pros-
tate cancer [11]. However, TES methylation status and
pathological function in GBM still remain largely un-
clear [12,13].
Herein, we examined the expression of TES in human
GBMs and investigated the biological role of TES in the
pathogenesis of this tumor. We found that TES was
down-regulated in both glioblastoma cell lines and GBM
tissues. TES expression level correlated inversely with the
clinical outcome. Our results also indicate that down-




All samples were collected from the Department of
Neurosurgery, Beijing Tiantan Hospital, between June
2009 and June 2012. Tissues were frozen in liquid nitro-
gen immediately after surgery; some were stored at −80?C
following the extraction of RNA, whereas others were
formalin-fixed and paraffin-embedded for immunohisto-
chemistry. Informed consent from patients and ethics ap-
proval from the ethics committee was achieved. This
study have been approved by the Review board of Beijing
Tiantan Hospital, Capital Medical University.
DNA methylation profiling
Methylation profiling was performed using the Illumina
Infinium Methylation27 Bead Array. The BeadChip contains27,578 highly informative CpG sites covering more than
14,000 human RefSeq genes. This allows searches to inter-
rogate all these sites per sample at a single nucleotide
resolution. Bisulfite modification of DNA, chip process-
ing, and data analysis were carried out by following
the manufacturer ? s manual. DNA was extracted from
peripheral-blood buffy coats using the QIAmp DNA
mini kit according to the manufacturer ? s protocol (Qiagen,
Valencia, CA, USA); the quality of DNA samples was
assessed by electrophoresis in a 1% agarose gel. DNA were
then bisulfite-modified using the EZ DNA methylation kit
(Zymo Research) and hybridized according to the manu-
facturer ? s instructions.
Immunohistochemistry
For immunohistochemistry, we used a standard avidin-
biotin-peroxidase complex method. Briefly, 4-μm thick
tissue sections were dewaxed and the endogenous per-
oxidase activity was blocked with 3% hydrogen peroxide
in deionized water. For antigen retrieval, sections were
immersed in an antigen repair liquid kit and then rinsed
in phosphate-buffered saline (PBS; pH 7.2). The sections
were incubated at 37?C for 1 h with anti-TES monoclo-
nal antibody. After rinsing in PBS, sections were incu-
bated with a goat anti-mouse secondary antibody for 30
min, and washed in PBS. A DAB coloration kit (ZSGB-
BIO ORIGENE, ZLI-9018) was then used; PBS was used
as a negative control. The percentage of positive tumor
cells was counted under a bright-field Olympus micro-
scope. Sections with fewer than 25% labeled cells indi-
cated low expression of TES. Sections with labeling of
≥25% indicated high expression of TES.
Cell lines and treatment with 5-Aza-2′-deoxycytidine
(5-aza-dC) treatment
Glioblastoma cell lines (U251) were routinely cultured
in Dulbecco? s modified eagle medium (Hyclone, Thermo
Scientific, USA). The medium was supplemented with 1%
L-glutamine (Hyclone), 10% fetal bovine serum (Gibco,
Invitrogen Corporation, Carlsbad, CA, USA), 1% penicillin
streptomycin (Hyclone), and grown at 37?C in a humidi-
fied atmosphere of 5% CO2/95% air. 5-aza-dC (Sigma
Aldrich Corporation, St Louis, MO, USA) was dissolved
in PBS (Hyclone) and filtered with a 0.22 μm filter
membrane.
Western blotting
U251 cells were lysed in 1% NP40 buffer (150 mM, 1%
NP40, 50 Mm Tris, pH 8.0) following treatment with
5-aza-dC; 30 μg of protein samples were loaded onto
10% SDS-PAGE gels and then transferred to polyvinyli-
dene fluoride membranes (Millipore). The membranes
were then blocked with skimmed milk in Tris-buffered sa-
line Tween-20 for 2 h. The following primary antibodies
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anti-b-tubulin (Sigma-Aldrich), followed by reaction with
a goat anti-mouse second antibody.
Flow cytometry analysis of cell apoptosis
Cell apoptosis was analyzed by an Annexin V-FITC⁄pro-
pidium iodide (PI) kit according to the manufacturer ? s
instructions. Briefly, harvested cells were resuspended
in 100 μL Annexin V-FITC binding buffer and adjusted
to about 1 ? 10 6 ⁄mL, then 5 μL Annexin V-FITC and 5 μL
PI (20 mg ⁄mL) were added and incubated for 15 min
at room temperature in the dark. Flow cytometry was con-
ducted on a fluorescence-activated cell sorter (FACSCalibur?
BD Biosciences, Hercules, CA, USA). Each experiment
was performed in triplicate.
Statistical analysis
Cox analysis was performed using Matlab2009. Survival
curves were calculated according to the Kaplan-Meier
method and differences between curves were assessed
using the log-rank test. The difference between high and
low TES-expressing tissues was assessed using the χ2 test.
Significant differences among groups were determined
using the Student? s t-test. P <0.05 was considered to be
significant. All statistical analyses were carried out using
the software GraphPad Prism (GraphPad Software, La
Jolla, CA, USA) and SPSS version 16.0 (SPSS, Chicago, IL,
USA).
Results and discussion
Identification of promoter hypermethylation of TES gene
in GBM
We performed genome-wide DNA methylation analysis
on 42 GBM and 8 normal brain tissues. To identify genesFigure 1 TES promoter methylation status in glioblastoma (GBM, n =
methylation microarray. (A) Comparison of TES promoter methylation sta
independent t-test analysis (down). (B) Western blot of TES in U251 cell lin
used as a protein loading control.that had different methylation status between pGBM
and normal tissues, all 50 methylation data were subjected
to Significant Analysis of Microarray and 42 GBM were an-
alyzed by Survival Analysis (Cox analysis) Metlab2009.
Overall, 21 differential genes displayed correlation be-
tween promoter methylation and the overall survival in
glioblastomas: TUBA2, CKMT2, AMT, HOXC11, TRIM58,
LCE1B, KLF14, SERPINB12, CYP2A7, TREML2, UNQ467,
SPRR3, TES, RGN, DEFA1, AJAP1, PDE4C, SPRR2D,
WNT7B, UBQLN3, and LCE1F. Independent t-test and
Kaplan-Meier method were performed on these genes
to identify the differentiation and prognostic value in
a univariate manner. Finally, eight genes were identified:
WNT7B, CKMT2, AMT, UNQ467, DEFA1, TUBA2, TES,
and UBQLN3. We selected the TES gene as the best can-
didate gene for further study (Figure 1A). To verify the
hypermethylation of TES in GBM, treatment with de-
methylation reagent 5-aza-dC on the GBM cell line U251
(low TES expression) can greatly increase TES expression
(Figure 1B). This result confirms the microarray data that
TES is hypermethylated in GBM.
Down-regulation of TES protein expression is in GBM tissues
TES protein expression in GBM was surveyed by immu-
nohistochemistry using anti-TES monoclonal antibody
on 37 independent GBM and 10 non-tumor samples.
A reduced TES protein level was found in 33 (89.2%)
tumor tissues and in 2 (20%) non-tumor tissues (P <0.001,
Figure 2A). For evaluation of TES protein level, classifica-
tion standards were as follows: high, >25% tumors cells
were positively stained, low, no staining or <25% tumor
cells showed negatively staining. Collectively, these results
demonstrated a significant down regulation of TES pro-
tein expression in GBM (P <0.001, Figure 2B).42) and normal (n = 8) samples analyzed by DNA promoter
tus in GBM and normal samples by microarray analysis (up) and
e before and after 5-aza-2-deoxycytidine treatment. Anti-tublin was
Figure 2 TES expression in GBM. (A) Immunohistochemical staining of TES protein expression in normal tissue (left) and a GBM specimen
(right) (magnification ? 400). (B) Collective summary of TES staining intensity from all samples.
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To evaluate pathogenic effect of low expression of TES
in GBM, apoptotic effect was assessed on 5 μm 5-aza-
dC treated and untreated U251 cells. The percentage of
apoptotic cells was calculated by flow cytometry using
the Annexin-V/PI double-staining assay (Figure 3A). In
the untreated control group (no 5-aza-dC was given),
the total rate of apoptosis was 8.75 (Figure 3B). How-
ever, in U251 cells treated with 5-aza-dC, many more
apoptotic cells were detected: the rate raised to 12.25,
suggesting that TES promotes apoptosis of glioblastoma
cells.
TES protein expression is highly correlated with worse
outcome of GBM patients
After TES promoter hypermethylation was identified in
some GBM patients, we further estimated the association
of this abnormality with GBM patients? survival using
Kaplan-Meier plot, as shown in Figure 4A. Results showed
that the overall survival (OS) of patients with TES hyper-
methylation is significantly shorter than those with hypo-
methylation (median survival, 236.5 vs. 565 days P <0.05,
log-rank test). Patient outcome was also evaluated inde-
pendently from TES protein expression level from results
of immunohistochemistry analysis. Patients with high TES
expression had a median OS of 221 days, while those with
low expression had an OS of 345 days (median survival,
221 vs. 345 days P <0.05; Figure 4B). These results suggest
that the down-regulation of TES predicts worse outcome
of GBM patients and that promoter hypermethylation
should be the major reason for TES down-regulation,although mutation, loss of heterozygosity, etc. cannot be
excluded.
The elucidation biomarkers of glioblastoma, the most
common and lethal of brain tumors, has been reported
since the 1990 ? s. Somatic mutations have been demon-
strated for TP53 on 17p [14-16], PTEN on 10q [17-19],
RB1 on 13q [20,21], and homozygous deletions of the
CDKN2A/p16/p14 locus on 9p have been documented
[16,22]. Other putative tumor-suppressor genes alter-
nated at all other loci remain elusive. Methylation of
promoter regions inducing silencing of gene expression,
has been implicated as an alternative mechanism for
tumor-suppressor gene inactivation. In glioblastomas, fre-
quent promoter hypermethylation has been reported for
PRDX1 [23,24], WNK2 [24], SGNE1 [25], and ALDH1A3
[26]. Blough et al. demonstrated that 1p Loss silence
NHE-1 in oligodendroglioma [27]. Some studies showed
the methylation of promoter regions with other alter-
ations. Chou et al. identified hypermethylation of RB1
with IDH1 and IDH2 mutation in gliomas [28].
The TES gene was previously identified as located in
the fragile chromosomal region FRA7G at 7q31.2 [29].
Loss of TES expression has been frequently found in vari-
ous cancers [5,29]. Non-synonymous mutation homozy-
gous deletions have not been observed, consistent with
CpG promoter hypermethylation being a mechanism of
TES gene inactivation [5]. Previous studies have demon-
strated that TES inhibited the growth of breast and uter-
ine cells and promoted ovarian cancer cell apoptosis
through caspase-dependent and caspase-independent pro-
cesses [9,30]. Although TES could be a candidate tumor
Figure 3 Cell apoptosis induced by treatment of 5-aza-2-deoxycytidine. The percentage of apoptotic cells was calculated by flow cytometry
using the Annexin-V/PI double-staining assay. Control vs. 5AZA (*P <0.05). (A) (Control) Apoptosis of U251 cells in the group without 5-aza-dC
treatment (8.75); (B) (5AZA) Apoptosis of U251 cells in the 5 mL 5-aza-2-dC group (15.25).
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role is still unknown.
TES, a highly conserved protein, consists of three C-terminal
LIM domains and a PET (prickle, espinas, and testin)
domain of unknown function. Group 3 LIM domainFigure 4 Survial analysis according to TES expression and methylatio
to the TES methylation status in 42 GBM patients (A) and according to theproteins, including the TES domain, are a component
of the focal adhesion complex and localize to cell-matrix
adhesions and cell-cell contacts [31]. Over-expression of
TES increases cell spreading and decreased cell motility
[32]. Adenoviral transduction of the TES gene into breastn status. Kaplan-Meier survival estimates of overall survival according
TES expression level in GBM patients (B).
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tumor reduction [30]. Further functional analysis demon-
strated that TES acted as a tumor suppressor gene in vivo,
as TES knockout mice showed an increased susceptibility
to induced gastric cancer [6]. Our results in this study
showed that TES is widely down-regulated in GBM. Eleva-
tion of TES expression can increase apoptosis of GBM
cells.
TES can be silenced either by loss of heterozygosity or
by promoter hypermethylation in several tumor types,
including head and neck squamous cell carcinoma, ovar-
ian cancer, primary gastric cancer, prostate cancer, breast
cancer, among others [8-12].
Our data suggests promoter hypermethylation is the
major cause of down-regulation or silencing of TES in
GBM, even if other mechanisms cannot be excluded at
this point.
Conclusions
Using whole-genome DNA methylation microarray we
found that the TES gene is a novel tumor suppressor
gene and might represent a valuable prognostic marker
for glioblastoma, indicating a potential future target for
GBM therapy.
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